Clinical value of geriatric nutritional risk index and pan-immune-inflammation value in locally advanced gastric cancer receiving neoadjuvant chemotherapy

Table 1 Patient characteristics and demographics in this study, n (%)/mean ± SD

Characteristics	Total (n = 147)	Mean (SD)	Range
Gender
Male	107 (72.79)
Female	40 (27.21)
Age, years		59.53 ± 9.91	26-82
< 65	101 (68.71)
≥ 65	46 (31.29)
BMI (kg/m2)		23.94 ± 3.09	15.04-32.39
Underweight	4 (2.72)
Normal	72 (48.98)
Overweight	56 (38.10)
Obese	15 (10.20)
Smoking history
No	67 (45.58)
Yes	80 (54.42)
Drinking history
No	85 (57.82)
Yes	62 (42.18)
NACT regimen
SOX	137 (93.20)
Others	10 (6.80)
Diabetes
No	122 (82.99)
Yes	25 (17.01)
Hypertension
No	103 (70.07)
Yes	44 (29.93)
Location
1/3 lower	89 (60.54)
1/3 middle	32 (21.77)
1/3 upper	11 (7.48)
Total	15 (10.20)
Clinical T stage
T2	15 (10.20)
T3	65 (44.22)
T4	67 (45.58)
Clinical N stage
N-	37 (25.17)
N+	110 (74.83)
Clinical stage
2	54 (36.73)
3	93 (63.27)
CEA, ng/mL		3.3 ± 3.52	0.56-33.31
CA19-9, U/mL		16.6 ± 20.63	0.6-159.5
hsCRP, mg/L		2.56 ± 4.75	0.14-28.43
GNRI		107.17 ± 10.56	56.23-162.83
PIV		170.35 ± 127.5	16.66-823.23
NRS2002 score
< 3	103 (70.07)
≥ 3	44 (29.93)
Vascular invasion
No	99 (67.35)
Yes	48 (32.65)
Perineural invasion
No	108 (73.47)
Yes	39 (26.53)
Pathological T stage
T0	22 (14.97)
T1	25 (17.01)
T2	35 (23.81)
T3	36 (24.49)
T4	29 (19.73)
Pathological N stage
N-	92 (62.59)
N+	55 (37.41)
Pathological stage
PCR	21 (14.29)
1	53 (36.05)
2	35 (23.81)
3	38 (25.85)
CAP
0	22 (14.97)
1	28 (19.05)
2	47 (31.97)
3	50 (34.01)
Complication
No	98 (66.67)
Yes	49 (33.33)

BMI: Body mass index; NACT: Neoadjuvant therapy; SOX: S-1 plus oxaliplatin; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; hsCRP: High-sensitivity C-reactive protein; GNRI: Geriatric nutritional risk index; PIV: Pan-immune-inflammation value; NRS2002: Nutritional Risk Screening 2002; PCR: Pathological complete response; CAP: College of American Pathologists.